Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/6/2024 | $21.00 → $13.50 | Neutral → Underperform | BofA Securities |
| 10/7/2024 | $23.00 | Neutral | UBS |
| 6/26/2024 | $25.00 | Overweight | Piper Sandler |
| 5/30/2024 | $28.00 | Outperform | Robert W. Baird |
| 5/30/2024 | $25.00 → $21.00 | Buy → Neutral | BofA Securities |
| 3/22/2024 | $20.00 | Outperform | Raymond James |
| 11/2/2023 | $8.00 → $9.00 | Neutral → Buy | BofA Securities |
| 6/6/2023 | $5.40 → $8.75 | Underperform → Neutral | BofA Securities |
4 - Oscar Health, Inc. (0001568651) (Issuer)
4 - Oscar Health, Inc. (0001568651) (Issuer)
4 - Oscar Health, Inc. (0001568651) (Issuer)
BofA Securities downgraded Oscar Health from Neutral to Underperform and set a new price target of $13.50 from $21.00 previously
UBS initiated coverage of Oscar Health with a rating of Neutral and set a new price target of $23.00
Piper Sandler initiated coverage of Oscar Health with a rating of Overweight and set a new price target of $25.00
4 - Oscar Health, Inc. (0001568651) (Issuer)
4 - Oscar Health, Inc. (0001568651) (Issuer)
4 - Oscar Health, Inc. (0001568651) (Issuer)
Oscar Health, Inc. ("Oscar") (NYSE:OSCR), a leading healthcare technology company, today announced it will bring the Oscar experience to more individuals, families, and businesses through the ACA marketplace in New Jersey in 2025. Oscar is introducing affordable health insurance products1 that empower everyone to pursue a healthy life on their terms with: Services built around personal health needs and cultural preferences. High-quality networks that align with their schedules, neighborhoods, and more. Technology solutions to help members make informed choices about their health. The Oscar experience will be available statewide starting January 1, 2025. Oscar has been a proud
For the quarter ended September 30, 2024: Total Revenue of $2.4 billion, a 68% increase year-over-year Medical Loss Ratio of 84.6%, an 80 bps increase year-over-year SG&A Expense Ratio of 19.0%, a 360 bps improvement year-over-year Net loss attributable to Oscar of $54.6 million, or $(0.22) of earnings per share, a $10.8 million improvement year-over-year Adjusted EBITDA loss of $11.6 million, an $8.7 million improvement year-over-year Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, today announced its financial results for the third quarter ended September 30, 2024. "Oscar reported positive third quarter results with stro
Oscar Health, Inc. ("Oscar") (NYSE:OSCR), a leading healthcare technology company, today announced it is entering the greater Charlotte and Winston-Salem areas of North Carolina to bring the Oscar experience to individuals and families through the ACA marketplace in 2025. Oscar is introducing easy, affordable health insurance1 options with: Services built around personal health needs and cultural preferences Atrium Health's high-quality networks that fit with their schedules, neighborhoods and more Technology solutions to help members make informed choices about their health The Oscar experience will be available in 12 North Carolina counties starting Jan. 1, 2025, including Anson,
Oscar Health, Inc. ("Oscar") (NYSE:OSCR), a leading healthcare technology company, announced that on January 22, 2024 the Compensation Committee of Oscar's Board of Directors approved the grant of employment inducement restricted stock unit awards covering an aggregate of 104,586 Class A shares of Oscar's common stock to 11 new non-executive employees of Oscar and its affiliates, to induce them to join Oscar and its affiliates. The awards generally vest quarterly over a one-year period following their vesting commencement date, subject to continued employment. The awards were granted under Oscar's 2022 Employment Inducement Award Plan as employment inducement awards pursuant to the New York
Oscar Health, Inc. ("Oscar") (NYSE:OSCR), the first health insurance company built around a full stack technology platform, today announced the appointment of two seasoned healthcare executives to round out its leadership bench and further propel its vision to refactor healthcare. Kerry Sain has joined the company as the Executive Vice President of +Oscar, effective August 14, 2023, and Steven Kelmar will join as Executive Vice President and Chief of Staff to the CEO, effective September 21, 2023. In her role, Sain oversees the go-to-market strategy for the +Oscar business and will work closely with Mario Schlosser, President of Technology and Chief Technology Officer, to continue externa
Oscar Health, Inc. ("Oscar") (NYSE:OSCR), the first health insurance company built on a full stack technology platform, today announced that Dr. Sean Martin, MD has been appointed to serve as the company's new Chief Medical Officer, effective immediately. Dr. Martin joined Oscar in 2016 and during his tenure has provided clinical leadership across a number of core clinical functions, including enterprise affordability, medical management, market performance, population health, and behavioral health. In his new role, he will be responsible for implementing Oscar's clinical capabilities and enhancing the quality of care and outcomes for its members. "Dr. Martin is an avid champion of the us
SC 13G/A - Oscar Health, Inc. (0001568651) (Subject)
SC 13G - Oscar Health, Inc. (0001568651) (Subject)
SC 13D/A - Oscar Health, Inc. (0001568651) (Subject)
10-Q - Oscar Health, Inc. (0001568651) (Filer)
8-K - Oscar Health, Inc. (0001568651) (Filer)
8-K - Oscar Health, Inc. (0001568651) (Filer)
Piper Sandler analyst Jessica Tassan maintains Oscar Health (NYSE:OSCR) with a Overweight and maintains $25 price target.
Across the recent three months, 7 analysts have shared their insights on Oscar Health (NYSE:OSCR), expressing a variety of opinions spanning from bullish to bearish. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 4 2 0 0 Last 30D 0 1 0 0 0 1M Ago 0 2 1 0 0 2M Ago 1 1 1 0 0 3M Ago 0 0 0 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $24.43, along with a high estimate of $28.00 and a low estimate of $21.00. Marking
Piper Sandler analyst Jessica Tassan initiates coverage on Oscar Health (NYSE:OSCR) with a Overweight rating and announces Price Target of $25.
For the quarter ended September 30, 2024: Total Revenue of $2.4 billion, a 68% increase year-over-year Medical Loss Ratio of 84.6%, an 80 bps increase year-over-year SG&A Expense Ratio of 19.0%, a 360 bps improvement year-over-year Net loss attributable to Oscar of $54.6 million, or $(0.22) of earnings per share, a $10.8 million improvement year-over-year Adjusted EBITDA loss of $11.6 million, an $8.7 million improvement year-over-year Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, today announced its financial results for the third quarter ended September 30, 2024. "Oscar reported positive third quarter results with stro
Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, will release its third quarter 2024 financial results before the market opens on Thursday, November 7, 2024. Management will review these results in a conference call beginning at 8:00 AM (ET). The call-in number and webcast link are as follows: Live Call: 1.888.596.4244 Conference ID: 7768132 Webcast Link The call will be archived and available on Oscar's investor relations website (ir.hioscar.com) following November 7, 2024 for a period of 90 days. About Oscar Health Oscar Health, Inc. ("Oscar") is a leading healthcare technology company built around a full stack technology platform an
For the quarter ended June 30, 2024: Total Revenue of $2.2 billion, a 46% increase YoY Medical Loss Ratio of 79.0%, a 90 bps improvement YoY SG&A Expense Ratio of 19.6%, a 260 bps improvement YoY Net income attributable to Oscar of $56.2 million, or $0.20 of diluted earnings per share, a $71.7 million improvement YoY Adjusted EBITDA of $104.1 million, a $68.6 million improvement YoY Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, today announced its financial results for the second quarter ended June 30, 2024. "Oscar reported strong second quarter results, closing out the best six months in the company's history," sa